History is repeating itself. After facing generic competition in the United States to its second-biggest product in 2006, Sanofi-Aventis is now dealing with a similar threat in Europe. Competition concerns came after Switzerland's Schweizerhall Holding AG announced it would launch a copy of the Plavix blood thinner that could be bought for a lower price. Schweizerhall said it expects German regulators to approve its generic version of Plavix, called clopidogrel.
Sanofi-Aventis's fears about generic competition are justified as the company had to fight against a similar situation less than a year ago. Back in 2006, Bristol-Myers Squibb Co. (NYSE: BMY), which develops the product with Sanofi, saw a big plunge in its sales after Canadian generics company Apotex Inc. launched a cut-price copy of the drug.
Shares of biotechnology company Gilead Sciences Inc. (NASDAQ: GILD) have been plunging this morning, despite the firm posting better-than-expected first quarter earnings per share. Hurting the stock this morning is the company's full-year sales guidance, which was unchanged.
Gilead Sciences reported late yesterday that its profit during the first-quarter jumped 22% to $496.1 million, or 51 cents per share, boosted by strong HIV treatments Atripla and Truvada sales. These numbers are up from $407.4 million, or 43 cents per share reported in the same period a year ago. Analysts' forecast was for lower earnings of 47 cents per share in the quarter.
The company's quarterly revenue also surged by a respectable 22% to $1.26 billion. For this period, the company benefited from strong gains from combination HIV treatment Atripla which came with sales of $342.2 million, a 70 percent rise. HIV drugs sales also saw a growth of 37% to $964.7 million. Analysts, on average, expected Gilead Sciences's sales to be $1.22 billion, according to Reuters Estimates.
Shares of drug maker Pfizer Inc. (NYSE: PFE) have been tumbling in early trading after reporting this morning a plunge of 18% in its first-quarter profit. The company's earnings numbers have been dragged down by lower sales of blood-pressure drug Norvasc and the allergy drug Zyrtec.
The company said its quarterly profit dropped to $2.78 billion, or 41 cents per share on strong generic competition. These numbers are down from $3.39 billion, or 48 cents per share reported in the same period a year ago. Excluding items, Pfizer's earnings would have come in at 61 cents per share, missing analysts' predictions for a profit of 66 cents per share in the quarter.
Pfizer's quarterly revenue also slipped 5% to $11.85 billion.The company attributed the revenue decline to its loss of U.S. exclusivity for blood pressure drug Norvasc. However, the drop in revenue could have been even worse if the drug maker hadn't benefited from the weak dollar, Pfizer stated. Analysts expected the company to show sales of $12.06 billion in the first quarter, according to Reuters Estimates.
Shares of drug company Abbott Laboratories Inc. (NYSE: ABT) were trading higher this morning after the company reported that its first-quarter profit jumped 35%, helped by strong international demand for its rheumatoid arthritis medication Humira. However, the stock is down 1% just before noon.
For the quarter, Abbott Laboratories reported that its profit climbed to $938 million, or 60 cents per share, boosted by higher sales of its prescription drugs and medical devices that benefited from favorable foreign exchange rates. Excluding special items, the company's earnings came in at 63 cents a share, beating analysts' estimations for quarterly earnings of 62 cents a share.
The pharmaceutical company also announced a 14% growth in revenues, to $6.77 billion, up from $5.95 billion a year earlier. Revenue during the period was helped by a 54% increase in its drug Humira sales which surged to $878 million in the first quarter. Analysts, on average, were expecting the company show $6.53 billion in revenue, according to Thomson Financial.
With traders increasingly worried about the housing market and the credit crunch, health products maker Johnson & Johnson (NYSE: JNJ) gave an optimistic note to Wall Street by posting a surprising growth in its first-quarter profit. The company reported better-than-expected earnings, with some help from favorable exchange rates.
For the quarter, the company said that its profit surged 40% to $3.6 billion, or $1.26 per share, helped by strong sales of many key products. These numbers are up from $2.57 billion, or 88 cents a share, reported in the same period a year earlier. Analysts, on average, expected the company to show quarterly earnings of $1.20 a share.
The health products maker posted growth of 7.7% for its first-quarter revenue, which climbed to $16.19 billion from $15.04 billion a year earlier. During the period, Johnson & Johnson benefited from the weak dollar which was a major driver for its consumer products sales. Analysts expected the company show revenue of $15.83 billion in the third quarter, according to Thomson Financial.
After hitting a one-year high of $59.17 in January, the stock hit a one-year low of $46.64 last week. NVS opened this morning at $50.21. So far today the stock has hit a low of $49.70 and a high of $50.44. As of 11:55, NVS is trading at $50.19, up $1.19 (2.4%). The chart for NVS looks bearish and steady, while S&P gives the stock a neutral 3 STARS (out of 5) hold rating.
For a bullish hedged play on this stock, I would consider a May bull-put credit spread below the $45 range. A bull-put credit spread is an options position that combines the purchase and sale of put options to hedge risk in case the stock doesn't do what you think but still leverage nice returns. For this particular trade, we will make a 6.4% return in just 2 months as long as NVS is above $45 at May expiration. Novartis would have to fall by more than 10% before we would start to lose money.
The company said its profit increased during the fourth quarter to $201.2 million, or 67 cents per share. This is a significant jump from the same period of last year when the company reported a profit of $108.6 million, or 32 cents per share. Included in Biogen's earnings figures were costs related to merger, and expenses related to the company's stock option.
Excluding that, the drugmaker's quarterly profit gained 45% and its earnings per share came in at 89 cents. Analysts were expecting the company show earnings of only 80 cents per share.
The Home Depot Inc (NYSE: HD) to report Q2 earnings; conference call at 9am. Home Depot is expected to post substantial Q2 revenue/EPS declines, but equally important will be the company's comments: with the housing sector expected to remain sluggish through at least late 2007, analysts will evaluate whether HD can overcome that headwind with a new focus on customer service, demographic trends that suggest increased home repair/remodeling, and 20-year high homeownership rates that suggest steady house goods demand.
Macy's Inc (NYSE: M) to report Q2 earnings; conference call at 10:30am.
PDUFA date for GPC Biotech's (NASDAQ: GPCB) Satraplatin for treatment of hormone refractory prostate cancer.
Thursday August 16
JC Penney Co Inc (NYSE: JCP) to report Q2 earnings; conference call at 9:30am.
Hewlett Packard Company (NYSE: HPQ) to report Q3 earnings; conference call at 5pm. Analysts will evaluate HPQ's ability to maintain momentum in its innovative imaging/printing group, which is expected to help HPQ post solid Q3 revenue gains.
GlaxoSmithKline's (NYSE: GSK) Alli, the first ever over-the-counter weight loss drug approved by the FDA, will be available in late June, almost hitting the market in time for this summer's bathing suit season.
The drug will likely become immediately popular, because it will be FDA tested and approved (unlike Trimspa and Hoodia), but available over-the counter (unlike Meridia and Xenical). Helping it to become a household name is the $150M+ marketing push the drug is getting this year. The advertising has already begun -- I saw an ad for Alli while researching GNC's website for this blog. This should be enough to bring the drug to the forefront of our obese culture's mind. However, the advertising won't be able to keep it there. Only results will.
And unlike past drug treatments for obesity, this one is being very upfront about what it is and isn't. It is not a magic pill, says the website, myalli.com, and the most active ingredient for it to work is you. This is both good and bad for Glaxo. The good news for the company is that they will not be told they are advertising the product falsely -- the website is all about how you have to be ready to change your lifestyle for it to work, and how if you don't, the drug will give you less than desirable side-effects. The bad news is that this is much less likely to be a blockbuster drug if it is not the miracle obesity pill the market has been dying for, which it sadly doesn't appear to be.
All in all, I'd say this is no home run, but a stand-up double for Glaxo. Alli will help those willing to work at it, and strengthen the company's consumer healthcare products segment, fitting in nicely with anti-smoking drug Nicoderm. It will not, if Alli's website is any indication, revolutionize dieting in our instant gratification seeking country.
(On a totally unrelated note, Google ought to sue Glaxo for copyright infringement -- the Alli logo strongly resembles Google's own logo. Although I guess Google would have a tough time with anything like that, with all the heat they are facing since taking over YouTube and all.)
No doubt by now you have heard the good news regarding Pfizer Inc. (NYSE:PFE) and the shield it has in place for Celebrex. You can get some more insight on that by reading Douglas McIntyre's post.
Now the time is ripe for Pfizer to do something powerful. If it can accomplish one or two block buster product releases before mid-year, it'll be off to the races once again. In pursuit of that goal, Pfizer has a large stable of potential ground shakers in development. Here's an encapsulated view of what Pfizer has going right now in R&D:
I counted 49 formulations that Pfizer has in PHASE I of development. Of those compounds, ten are intended cancer treatments, eight are for inflammation and / or pain, including arthritis, 11 are directed towards cardiology, metabolic and endocrine conditions. Pfizer also has six compounds in PHASE I that are indicated for infectious diseases. Phase one drug testing focuses on compound safety rather than drug effectiveness.
There's a very interesting feature over at The Motley Fool and I find it very useful . The CAPS community stock rating pages give highly understandable insight plus gems of investor feedback which help to bring the knowledge about individual stocks to a layman's level. Investment players like me benefit from this feature.
La Jolla Pharmaceutical Company (NASDAQ:LJPC) has the CAPS number one spot this weekend based on a 43.1% stock value spike fueled by moderately positive interim results in a phase III study of its number one product Riquent. The drug in question shows promise in the treatment of Lupus, a chronic inflammatory disease that can cause organ malfunction. However, analysts are skeptical regarding the value of this phase III test result as a basis for developing a strong position in the company.
Even those investors who express a positive mood, unwittingly show reservations about whether or not the LJPC spike can be supported. Analyst consensus is "hold" on LJPC stock and neutral on the company. It is worthy of note that an Associated Press news release regarding the LJPC test results states: "Several drug makers are in advanced stage trials for lupus drugs. To date, no specific lupus drug has been approved in the United States."(emphasis mine)
I myself expect LJPC share value to recede quickly and I would base my choices on that belief. I see nothing else of interest in the company's fundamentals... at least not to the positive side. If I had shares of JLPC which I purchased at bargain, I'd be tempted to unload half of them immediately to reap some of the current gain. If I had bought those shares for a higher price, I'd be comfortable holding on to them for a while just to see what develops.
Not a day after Wal-Mart Stores' (NYSE:WMT) announcement it is cutting generic drug prices to $4 in Florida, Target Corp (NYSE:TGT) said it would immediately match these lower prices. Seems Target wants to offer everyday low prices too.
If pharmacy chains thought they were in trouble after Wal-Mart's announcement, their troubles have just doubled. As for Wal-Mart, its competitive edge had just been diluted.
The 300 drugs Wal-Mart had mentioned consist of commonly-prescribed ones, and will be offered for as little as $4 a month. Sixty-five Wal-Mart, Neighborhood Market and Sam's Club stores in the Tampa Bay area are supposed to start the program today. The program will be expanded to all of Florida by January and nationwide by next year.
Target didn't say if it would also expand its offer to match Wal-Mart, but if we read the statement it issued correctly, then Target will always be price-competitive with Wal-Mart.
While Wal-Mart's motives could be related to attempts to improve its embattled public image, Target's motives are clear, and neither are altruistic. But as long as the customers can benefit -- even if Wal-Mart and Target's customers come from different demographics -- the motives aren't that important, or are they?
Perhaps coming from Canada, where a system of public health-care exists, I can't properly relate to all this. I grind my teeth when I hear of big corporations trying to take advantage of poor health-care services while increasing their own profits.
Shares of French drug maker Sanofi-Aventis (NYSE: SNY) have been tumbling more than 5% in morning trading on news that a Swiss drug maker said it expects to receive approval to sell a generic version of Sanofi's anti-clotting agent Plavix.
Shares of biotechnology company 
Shares of drug maker 
Shares of drug company 
With traders increasingly worried about the housing market and the credit crunch, health products maker 
Shares of drugmaker .gif){kind=logo}
.gif){kind=logo}
Just how high will U.S. gasoline prices rise?
Nordstrom and Kohl's post smaller-than-expected Q1 profit declines
Oil hits record $127.43 on supply concerns, raised Goldman forecast
